The recommendation of betula verrucosa is the first NICE approval for an under-the-tongue immunotherapy for these conditions. Unlike conventional treatments that merely mask symptoms, this ...

Around 5,700 people with early breast cancer are set to benefit from expanded access to a treatment combination designed to help prevent their cancer from returning, following our recommendation, ...

The technologies, which have been conditionally recommended in draft guidance, can help detect vertebral fragility fractures (VFFs) on medical images taken for unrelated condition. This means they ...

We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing ...

Licensed for use in the UK in March, Alyftrek will now be immediately funded by the NHS in England. This rapid timeline demonstrates NICE's commitment to getting breakthrough treatments to patients ...

We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing ...

Access to a range of journals, databases and other evidence-based resources for health and social care staff in England.

Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway. Last reviewed: 01 May ...

This guideline covers assessing risk of falling and interventions to prevent falls in all people aged 65 and over, and people aged 50 to 64 who are at higher risk of falls. It aims to reduce the risk ...

This guideline covers nutrition and weight management in pregnancy for anyone who may become pregnant, is planning to become pregnant or is already pregnant, and nutrition in children up to 5 years.

Check to see if you're entitled to access a range of content purchased by the NHS. If you are eligible, you can register for an OpenAthens account using our online form.

Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults. Last reviewed: 13 November 2024 Next review: This guidance ...